Engineered immune cells take aim at Mesothelin-Positive tumors
NCT ID NCT05451849
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This trial tests a new cell therapy called TC-510 for people with advanced cancers that have a protein called mesothelin on their surface, including mesothelioma, ovarian cancer, and pancreatic cancer. TC-510 uses a patient's own immune cells, which are genetically modified to better recognize and attack cancer cells while also turning a cancer defense signal into an activating signal. The study aims to see if this approach is safe and whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- TC-510 (a genetically engineered T-cell therapy)
- What this could lead to
- If successful, this could point toward a new treatment option for several hard-to-treat cancers that express mesothelin.
- What could go wrong
- This is an early-phase trial with only 14 participants, so results may not apply broadly. Cell therapies can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
14 people
The number who actually took part.
- Started
-
Jun 2022
- Finished
-
Aug 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient is \> 18 years of age at the time the Informed Consent is signed. * Patient has a pathologically confirmed diagnosis of either MPM, Serous Ovarian Adenocarcinoma, Pancreatic Adenocarcinoma, TNBC, and Colorectal Cancer * Patient's tumor has been reviewed with confirmed positive MSLN expression on \>/= 50% of tumor cells that are 1+, 2+ and/or 3+ by immunohistochemistry. Patients with epithelioid MPM, confirmation of MSLN expression is not required prior to enrollment. * Prior to TC-510 infusion, patients must have received at least 1 but no more than 5 systemic therapies for metastatic or unresectable disease with more details provided in the protocol * Patients has an ECOG performance status 0 or 1 * Patient is fit for leukapheresis and has adequate venous access for the cell collection. * Patient must have adequate organ function as indicated by the laboratory values in the clinical protocol Exclusion Criteria: * Inability to follow the procedures of the study * Known or suspected non-compliance, drug, or alcohol use
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Montefiore Einstein Cancer Center
The Bronx, New York, 10461, United States
-
National Cancer Institute
Bethesda, Maryland, 20814, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
University of California, San Francisco
San Franciso, California, 94143, United States
-
University of Miami
Miami, Florida, 33146, United States
-
University of Minnesota, Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
-
University of Oklahoma
Oklahoma City, Oklahoma, 73104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own immune cells fight ovarian cancer?
- Ovarian Cancer's spread: scientists probe abdominal fluid for clues
- Two-Drug combo targets stubborn KRAS lung cancer
- New PET tracer aims to light up hidden cancer targets
- Smaller chest drain may speed recovery after lung cancer surgery
- Can Real-World data match trial results for pembrolizumab in Triple-Negative breast cancer?